Blue Note Therapeutics raises $26M to help treat cancer-related distress via cognitive behavioral stress management (CBSM)

By SharpBrains | March 9, 2021

Blue Note Ther­a­peu­tics Rais­es $26.25 Mil­lion in Series A Financ­ing (press release): Blue Note Ther­a­peu­tics, Inc., today announced the clos­ing of a Series A financ­ing round of $26.25 mil­lion. Pro­ceeds will allow the com­pa­ny to scale the orga­ni­za­tion and fund near-term clin­i­cal tri­als of its lead pre­scrip­tion dig­i­tal ther­a­peu­tic (PDT), which will poten­tial­ly improve the…

Read More